LivaNova Q4 2019 Earnings Report
Key Takeaways
LivaNova PLC reported a decrease in worldwide sales by 3.2 percent and a GAAP diluted loss per share of $2.96 for Q4 2019. The adjusted diluted earnings per share were $1.00. The company faced challenges due to a component supplier issue for oxygenators and execution problems in the Rest of World region.
Worldwide sales decreased by 3.2 percent on a reported basis.
GAAP diluted loss per share from continuing operations was $2.96.
Adjusted diluted earnings per share from continuing operations were $1.00.
Strong sales in Advanced Circulatory Support (ACS) and stability in the Epilepsy business were noted.
LivaNova
LivaNova
LivaNova Revenue by Segment
LivaNova Revenue by Geographic Location
Forward Guidance
LivaNova anticipates sales growth between 3 and 5 percent on a constant-currency basis and adjusted diluted earnings per share in the range of $3.10 to $3.30 for full-year 2020. Adjusted cash flow from operations, excluding litigation payments, is projected to be $180 to $200 million, with capital expenditures ranging from $25 to $35 million.
Positive Outlook
- Expects worldwide net sales from continuing operations for full-year 2020 to grow between 3 and 5 percent on a constant-currency basis.
- Adjusted diluted earnings per share from continuing operations for 2020 are expected to be in the range of $3.10 to $3.30.
- Adjusted cash flow from operations, excluding litigation payments, will be in the range of $180 to $200 million.
- Capital expenditures are projected to range between $25 to $35 million.
- Focused on delivering higher sales growth, expanding gross margins and improving cash generation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income